Appointment of Financial Adviser for Strategic Review
Open PDF
| Stock | Chimeric Therapeutics Ltd (CHM.ASX) |
|---|---|
| Release Time | 1 Jul 2026, 9:01 a.m. |
| Price Sensitive | Yes |
This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA.
The summaries are generated by large language models so please interpret with care.
Chimeric Therapeutics Appoints Financial Adviser for Strategic Review
Key Points
- Chimeric Therapeutics has appointed Hawkesbury Partners as its Independent Financial Adviser
- The review aims to maximize shareholder value
- Potential strategic options include partnerships, funding, licensing, and mergers
Full Summary
Chimeric Therapeutics Limited, a leading Australian cell therapy company, has appointed Hawkesbury Partners Pty Limited as its Independent Financial Adviser to undertake a strategic review aimed at maximizing shareholder value. The Board believes the value embedded in Chimeric's clinical programs and infrastructure is not currently reflected in the Company's market capitalization. Hawkesbury Partners' mandate includes identifying and evaluating opportunities to monetize and realize value for Chimeric, potentially through strategic partnerships, funding, licensing arrangements, co-development agreements, mergers, asset sale transactions, and alternative capital structures.
Sign in to get more information about the company, including guidance changes and other insights.
Sign In